Literature DB >> 9547763

Prenatal exposure to amphetamines. Risks and adverse outcomes in pregnancy.

M A Plessinger1.   

Abstract

Based on findings in humans and the confirmation of prenatal exposures in animals, amphetamines and methamphetamines increase the risk of an adverse outcome when abused during pregnancy. Clefting, cardiac anomalies, and fetal growth reduction deficits that have been seen in infants exposed to amphetamines during pregnancy have all been reproduced in animal studies involving prenatal exposures to amphetamines. The differential effects of amphetamines between genetic strains of mice and between species demonstrate that pharmacokinetics and the genetic disposition of the mother and developing embryo can have an enormous influence on enhancing or reducing these potential risks. The effects of prenatal exposure to amphetamines in producing altered behavior in humans appear less compelling when one considers other confounding variables of human environment, genetics, and polydrug abuse. In view of the animal data concerning altered behavior and learning tasks in comparison with learning deficits observed in humans, the influence of the confounding variables in humans may serve to increase the sensitivity of the developing embryo/fetus to prenatal exposure to amphetamines. These factors and others may predispose the developing conceptus to the damaging effects of amphetamines by actually lowering the threshold of susceptibility at the sites where damage occurs. Knowledge of the effects of prenatal exposure of the fetus and the mother to designer amphetamines is lacking. Based on the few studies in which designer drugs have been examined in animal models, more questions are raised than answered. Possible reasons why no malformations or significant fetal effects were found in the study by St. Omer include the genetic strain of rat used, the conservative exposure profile, or the fact that the placenta metabolized MDMA before reaching the embryo. These questions underscore the need for further investigations concerning the prenatal exposure effects of designer compounds and the effects of amphetamine and methamphetamine in general.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9547763     DOI: 10.1016/s0889-8545(05)70361-2

Source DB:  PubMed          Journal:  Obstet Gynecol Clin North Am        ISSN: 0889-8545            Impact factor:   2.844


  33 in total

1.  Methamphetamine and other substance use during pregnancy: preliminary estimates from the Infant Development, Environment, and Lifestyle (IDEAL) study.

Authors:  Amelia M Arria; Chris Derauf; Linda L Lagasse; Penny Grant; Rizwan Shah; Lynne Smith; William Haning; Marilyn Huestis; Arthur Strauss; Sheri Della Grotta; Jing Liu; Barry Lester
Journal:  Matern Child Health J       Date:  2006-01-05

2.  Periventricular leukomalacia and prenatal methamphetamine exposure: a case report.

Authors:  Cary R Murphy; Edward F Bell; Yutaka Sato; Jonathan M Klein
Journal:  Am J Perinatol       Date:  2007-02-15       Impact factor: 1.862

Review 3.  Drugs, biogenic amine targets and the developing brain.

Authors:  Aliya L Frederick; Gregg D Stanwood
Journal:  Dev Neurosci       Date:  2009-04-17       Impact factor: 2.984

Review 4.  Roles for neuronal and glial autophagy in synaptic pruning during development.

Authors:  Ori J Lieberman; Avery F McGuirt; Guomei Tang; David Sulzer
Journal:  Neurobiol Dis       Date:  2018-04-28       Impact factor: 5.996

5.  The effects of prenatal methamphetamine exposure on childhood growth patterns from birth to 3 years of age.

Authors:  Rachel Zabaneh; Lynne M Smith; Linda L LaGasse; Chris Derauf; Elana Newman; Rizwan Shah; Amelia Arria; Marilyn Huestis; William Haning; Arthur Strauss; Sheri Della Grotta; Lynne M Dansereau; Hai Lin; Charles Neal; Barry M Lester
Journal:  Am J Perinatol       Date:  2011-08-04       Impact factor: 1.862

Review 6.  A developmental comparison of the neurobehavioral effects of ecstasy (MDMA).

Authors:  Brian J Piper
Journal:  Neurotoxicol Teratol       Date:  2006-10-20       Impact factor: 3.763

Review 7.  Fetal effects of psychoactive drugs.

Authors:  Amy L Salisbury; Kathryn L Ponder; James F Padbury; Barry M Lester
Journal:  Clin Perinatol       Date:  2009-09       Impact factor: 3.430

Review 8.  Neuro-obstetrics: A multidisciplinary approach to care of women with neurologic disease.

Authors:  Ingrid A Brussé; Anna C M Kluivers; Maria D Zambrano; Kara Shetler; Eliza C Miller
Journal:  Handb Clin Neurol       Date:  2020

Review 9.  Exposure to attention deficit hyperactivity disorder medications during pregnancy.

Authors:  Caitlin Humphreys; Facundo Garcia-Bournissen; Shinya Ito; Gideon Koren
Journal:  Can Fam Physician       Date:  2007-07       Impact factor: 3.275

10.  Neonatal amphetamine exposure and hippocampus-mediated behaviors.

Authors:  Andrew M Smith; Wei-Jung A Chen
Journal:  Neurobiol Learn Mem       Date:  2009-01-23       Impact factor: 2.877

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.